Catechol O-methyltransferase and monoamine oxidase A genotypes, and plasma catecholamine metabolites in bipolar and schizophrenic patients

Neurochemistry International

Volumn 56, Issue 6-7, 2010, Pages 774-779

  Zumárraga, Mercedes ^a   Dávila, Ricardo ^a   Basterreche, Nieves ^a   Arrue, Aurora ^a   Goienetxea, Biotza ^a   Zamalloa, María I ^a   Erkoreka, Leire ^b   Bustamante, Sonia ^b   Inchausti, Lucía ^b   González Torres, Miguel A ^b   Guimón, José ^c  

^a Hospital Psiquiatrico de Zamudio   (Spain)

^b HOSPITAL DE BASURTO   (Spain)

^c UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

Author keywords

3,4 dihydroxyphenylacetic acid; 3 methoxy 4 hydroxyphenylglycol; Bipolar disorder; Catechol O methyltransferase; Genetic polymorphism; Homovanillic acid; Monoamine oxidase A; Schizophrenia

Indexed keywords

3,4 DIHYDROXYPHENYLACETIC ACID; 4 HYDROXY 3 METHOXYPHENYLETHYLENE GLYCOL; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; CATECHOL METHYLTRANSFERASE; CATECHOLAMINE; HOMOVANILLIC ACID; MONOAMINE;

ADULT; AMINO ACID SUBSTITUTION; ARTICLE; BIPOLAR DISORDER; CATECHOLAMINE BLOOD LEVEL; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC REGULATION; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOAMINE METABOLISM; MUTATIONAL ANALYSIS; PATHOGENESIS; PRIORITY JOURNAL; SCHIZOPHRENIA; VARIABLE NUMBER OF TANDEM REPEAT;

3,4-DIHYDROXYPHENYLACETIC ACID; ADULT; AGED; ANALYSIS OF VARIANCE; BIPOLAR DISORDER; CATECHOL O-METHYLTRANSFERASE; CATECHOLAMINES; FEMALE; GENOTYPE; HOMOVANILLIC ACID; HUMANS; MALE; METHOXYHYDROXYPHENYLGLYCOL; MIDDLE AGED; MINISATELLITE REPEATS; MONOAMINE OXIDASE; POLYMORPHISM, GENETIC; PROMOTER REGIONS, GENETIC; SCHIZOPHRENIA;

EID: 77952288204     PISSN: 01970186     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuint.2010.02.015     Document Type: Article

References (47)

1. Akil M., Kolachana S., Rothmond D.A., Hyde T.M., Weinberger D.R., Kleinman J.E. Catechol-O-methyltransferase genotype and dopamine regulation in the human brain. J. Neurosci. 2003, 23:2008-2013.
2. Balciuniene J., Emilsson L., Oreland L., Pettersson U., Jazin E. Investigation of the functional effect of monoamine oxidase polymorphisms in human brain. Hum. Genet. 2002, 110:1-7.
3. Basterreche N., Dávila R., Zumárraga M., Arrúe A., González-Torres M.A., Zamalloa M.I., Anguiano J.B., Guimón J. Biological correlates of the congruence and incongruence of psychotic symptoms in patients with type 1 bipolar disorder. Neuropsychobiology 2008, 58:111-117.
4. Bowers M.B., Kantrowitz J.T. Elevated plasma dopamine metabolites in cannabis psychosis. Am. J. Psychiatry 2007, 164:1615-1616.
5. Cases O., Seif I., Grimsby J., Gaspar P., Chen K., Pournin S., Müller U., Aguet M., Babinet C., Shih J.C. Aggressive behavior and altered amounts of brain serotonin and norepinephrine in mice lacking MAOA. Science 1995, 268:1763-1766.
6. Caspi A., McClay J., Moffitt T.E., Mill J., Martin J., Craig I.W., Taylo R.A., Poulton R. Role of genotype in the cycle of violence in maltreated children. Science 2002, 297:851-854.
7. Castro-Fornieles J., Deulofeu R., Baeza I., Casulà V., Saura B., Lázaro L., Puig J., Toro J., Bernardo M. Psychopathological and nutritional correlates of plasma homovanillic acid in adolescents with anorexia nervosa. J. Psychiatry Res. 2008, 42:213-220.
8. Chen J., Lipska B.K., Halim N., Ma Q.D., Matsumoto M., Melhem S., Kolachana B.S., Hyde T.M., Herman M.M., Apud J., Egan M.F., Kleinman J.E., Weinberger D.R. Functional analysis of genetic variation in catechol-O-methyltransferase (COMT): effects on mRNA, protein, and enzyme activity in postmortem human brain. Am. J. Hum. Genet. 2004, 75:807-821.
9. Davidson M., Kahn R.S., Powchik P., Warne P., Losonczy M.F., Kaminsky R., Apter S., Jaff S., Davis K.L. Changes in plasma homovanillic acid concentrations in schizophrenic patients following neuroleptic discontinuation. Arch. Gen. Psychiatry 1991, 48:73-76.
10. Dávila R., Zumárraga M., Basterreche N., Arrue A., Anguiano J.B. Plasma Homovanillic acid levels in schizophrenic patients: correlation with negative symptoms. Psychiatry Res. 2007, 151:163-168.
11. Davis B.A., Durden D.A., O'Reilly R.L. The effect of age, sex, weight and height on the plasma concentrations in healthy subjects of the acidic metabolites of some biogenic monoamines involved in psychiatric and neurological disorders. Prog. Neuropsychopharmacol. Biol. Psychiatry 1991, 15:503-512.
12. Deckert J., Catalano M., Syagailo Y.V., Bosi M., Okladnova O., Di Bella D., Nöthen M.M., Maffe i.P., Franke P., Fritze J., Maier W., Propping P., Beckmann H., Bellodi L., Lesch K.P. Excess of high activity monoamine oxidase A gene promoter alleles in female patients with panic disorder. Hum. Mol. Genet. 1999, 8:621-624.
13. DeMille M.M., Kidd J.R., Ruggeri V., Palmatier M.A., Goldman D., Odunsi A., Okonofua F., Grigorenko E., Schulz L.O., Bonne-Tamir B., Lu R.B., Parnas J., Pakstis A.J., Kidd K.K. Population variation in linkage disequilibrium across the COMT gene considering promoter region and coding region variation. Hum. Genet. 2002, 111:521-537.
14. Diaz-Asper C.M., Goldberg T.E., Kolachana B.S., Straub R.E., Egan M.F., Weinberger D.R. Genetic variation in catechol-O-methyltransferase: effects on working memory in schizophrenic patients, their siblings, and healthy controls. Biol. Psychiatry 2008, 63:72-79.
15. Egan M.F., Goldberg T.E., Kolachana B.S., Callicott J.H., Mazzanti C.M., Straub R.E., Goldman D., Weinberger D.R. Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia. Proc. Natl. Acad. Sci. U.S.A. 2001, 98:6917-6922.
16. Gerra G., Leonardi C., Cortese E., Zaimovic A., Dell'agnello G., Manfredini M., Somaini L., Petracca F., Caretti V., Saracino M.A., Raggi M.A., Donnini C. Homovanillic acid (HVA) plasma levels inversely correlate with attention deficit-hyperactivity and childhood neglect measures in addicted patients. J. Neural Transm. 2007, 114:1637-1647.
17. Giltay E.J., Kho K.H., Blansjaar B.A., Verbeek M.M., Geurtz P.B., Geleijnse J.M., Gooren L.J. The sex difference of plasma homovanillic acid is unaffected by cross-sex hormone administration in transsexual subjects. J. Endocrinol. 2005, 187:109-116.
18. Glazer W.M., Bowers M.B., Charney D.S., Heninger G.R. The effect of neuroleptic discontinuation on psychopathology, involuntary movements, and biochemical measures in patients with persistent tardive dyskinesia. Biol. Psychiatry 1989, 26:224-233.
19. Gogos J.A., Morgan M., Luine V., Santha M., Ogawa S., Pfaff D., Karayiorgou M. Catechol-O-methyltransferase-deficient mice exhibit sexually dimorphic changes in catecholamine levels and behavior. Proc. Natl. Acad. Sci. U.S.A. 1998, 95:9991-9996.
20. Gutiérrez B., Bertranpetit J., Guillamat R., Vallès V., Arranz M.J., Kerwin R., Fañanás L. Association analysis of the catechol O-methyltransferase gene and bipolar affective disorder. Am. J. Psychiatry 1997, 154:113-115.
21. Hosák L. Role of the COMT gene Val158Met polymorphism in mental disorders: a review. Eur. Psychiatry 2007, 22:276-281.
22. Hunneman D.H., Jonas W., Gabriel M., Gahr M. Effect of age on homovanillic and 4-hydroxy-3-methoxymandelic acid levels in plasma. Eur. J. Pediatr. 1986, 145:555-557.
23. Jonsson E.G., Norton N., Forslund K., Mattila-Evenden M., Rylander G., Asberg M., Owen M.J., Sedvall G.C. Association between a promoter variant in the monoamine oxidase A gene and schizophrenia. Schizophr. Res. 2003, 61:31-37.
24. Kim Y.K., Kim L., Lee M.S. Relationships between interleukins, neurotransmitters and psychopathology in drug-free male schizophrenics. Schizophr. Res. 2000, 44:165-175.
25. Lachman H.M., Papolos D.F., Saito T., Yu Y.M., Szumlanski C.L., Weinshilboum R.M. Human catechol-O-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders. Pharmacogenetics 1996, 6:243-250.
26. Markianos M., Panas M., Kalfakis N., Vassilopoulos D. Plasma homovanillic acid and prolactin in Huntington's disease. Neurochem. Res. 2009, 34:917-922.
27. Mattay V.S., Goldberg T.E., Fera F., Hariri A.R., Tessitore A., Egan M., Kolachana B., Callicott J.H., Weinberger D.R. Catechol O-methyltransferase val158-met genotype and individual variation in the brain response to amphetamine. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:6186-6191.
28. Oeltmann T., Carson R., Shanon J.R., Ketch T., Robertson D. Assessment of O-methylated catecholamines levels in plasma and urine for diagnosis of autonomic disorders. Auton. Neurosci. 2004, 116:1-10.
29. Okamoto T., Yoshimura R., Ikenouchi-Sugita A., Hori H., Umene-Nakano W., Inoue Y., Ueda N., Nakamura J. Efficacy of electroconvulsive therapy is associated with changing blood levels of homovanillic acid and brain-derived neurotrophic factor (BDNF) in refractory depressed patients: a pilot study. Prog. Neuropsychopharmacol. Biol. Psychiatry 2008, 32:1185-1190.
30. Pickar D., Labarca R., Doran A.R., Wolkowitz O.M., Roy A., Breier A., Linnoila M., Paul S.M. Longitudinal measurement of plasma homovanillic acid levels in schizophrenic patients. Correlation with psychosis and response to neuroleptic treatment. Arch. Gen. Psychiatry 1986, 43:669-676.
31. Rizzo V., Melzi-d'Eril G.V. Determination of free 3-methoxy-4-hydroxyphenylethyleneglycol in plasma and in cerebrospinal fluid by liquid chromatography with coulometric detection. Clin. Chem. 1987, 33:844-845.
32. Rotondo A., Mazzanti C., Dell'Osso L., Rucci P., Sullivan P., Bouanani S., Gonnelli C., Goldman D., Cassano G.B. Catechol o-methyltransferase, serotonin transporter, and tryptophan hydroxylase gene polymorphisms in bipolar disorder patients with and without comorbid panic disorder. Am. J. Psychiatry 2002, 159:23-29.
33. Rybakowski J.K., Borkowska A., Czerski P.M., Hauser J. Eye movement disturbances in schizophrenia and a polymorphism of catechol-O-methyltransferase gene. Psychiatry Res. 2002, 113:49-57.
34. Sabol S.Z., Hu S., Hamer D. A functional polymorphism in the monoamine oxidase A gene promoter. Hum. Genet. 1998, 103:273-279.
35. Schulze T.G., Muller D.J., Krauss H., Scherk H., Ohlraun S., Syagailo Y.V., Windemuth C., Neidt H., Grassle M., Papassotiropoulos A., Heun R., Nothen M.M., Maie R.W., Lesch K.P., Rietschel M. Association between a functional polymorphism in the monoamine oxidase A gene promoter and major depressive disorder. Am. J. Med. Genet., Part B, Neuropsychiatr. Genet. 2000, 96:801-803.
36. Shifman S., Bronstein M., Sternfeld M., Pisanté-Shalom A., Lev-Lehman E., Weizman A., Reznik I., Spivak B., Grisaru N., Karp L., Schiffer R., Kotler M., Strous R.D., Swartz-Vanetik M., Knobler H.Y., Shinar E., Beckmann J., Yakir B., Risch N., Zak N.B., Darvasi A. A highly significant association between a COMT haplotype and schizophrenia. Am. J. Hum. Genet. 2002, 71:1296-1302.
37. Steinberg J.L., Garver D.L., Moeller F.G., Raese J.D., Orsulak P.J. Serum homovanillic acid levels in schizophrenic patients and normal control subjects. Psychiatry Res. 1993, 48:93-106.
38. Sumiyoshi T., Hasegawa M., Jayathilake K., Meltzer H.Y. Sex differences in plasma homovanillic acid levels in schizophrenia and normal controls: relation to neuroleptic resistance. Biol. Psychiatry 1997, 41:560-566.
39. Syagailo Y.V., Stober G., Grassle M., Reimer E., Knapp M., Jungkunz G., Okladnova O., Meyer J., Lesch K.P. Association analysis of the functional monoamine oxidase A gene promoter polymorphism in psychiatric disorders. Am. J. Med. Genet., Part B, Neuropsychiatr. Genet. 2001, 105:168-171.
40. Tunbridge E.M., Weickert C.S., Kleinman J.E., Herman M.M., Chen J., Kolachana B.S., Harrison P.J., Weinberger D.R. Catechol-o-methyltransferase enzyme activity and protein expression in human prefrontal cortex across the postnatal lifespan. Cereb. Cortex 2007, 17:1206-1212.
41. Walker E.F., Bonsall R., Walder D.J. Plasma hormones and catecholamine metabolites in monozygotic twins discordant for psychosis. Neuropsychiatry Neuropsychol. Behav. Neurol. 2002, 15:10-17.
42. Weinshilboum R.M., Otterness D.M., Szumlanski C.L. Methylation pharmacogenetics: catechol O-methyltransferase, thiopurine methyltransferase, and histamine N-methyltransferase. Annu. Rev. Pharmacol. Toxicol. 1999, 39:19-52.
43. Williams P.D., Puddey I.B., Beilin L.J., Vandongen R. Genetic influences on plasma catecholamines in human twins. J. Clin. Endocrinol. Metab. 1993, 77:794-799.
44. Yoshimura R., Nakano Y., Hori H., Ikenouchi A., Ueda N., Nakamura J. Effect of risperidone on plasma catecholamine metabolites and brain-derived neurotrophic factor in patients with bipolar disorders. Hum. Psychopharmacol. 2006, 21:433-438.
45. Zumárraga M., Andía I., Bárcena B., Dávila R. Determinación simultánea de dopamina y ácido 3,4 dihidroxifenilacético en orina por HPLC y detección amperométrica. Biométrica 1984, 3:109-120.
46. Zumárraga M., Andía I., Dávila R., Zamalloa M.I. Homovanillic acid in plasma determined by HPLC with direct injection of plasma filtrates. Clin. Chem. 1994, 40:2119-2120.
47. Zumárraga M., Dávila R., González-Torres M.A., Anguiano J.B., Zabalo M.J., Basterreche N., Arrue A., Zamalloa M.I., Guimón J. Inter- and intra-individual variability in the levels of plasma homovanillic acid in schizophrenic patients. Prog. Neuropsychopharmacol. Biol. Psychiatry 2007, 31:713-719.